MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH Has $12.61 Million Stake in Amgen Inc. $AMGN

Key Points

• MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH increased its stake in Amgen Inc. by 9.5% during Q2, now owning 45,160 shares valued at approximately $12.61 million.
• Institutional investors collectively own 76.5% of Amgen's stock, with several firms, including Brighton Jones LLC and Virtue Capital Management LLC, recently boosting their stakes.
• Amgen's latest quarterly earnings surpassed expectations, reporting $6.02 EPS and revenue of $9.18 billion, leading to a positive forecast for FY 2025 at 20.200-21.300 EPS.

MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH boosted its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 9.5% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 45,160 shares of the medical research company's stock after buying an additional 3,922 shares during the quarter. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH's holdings in Amgen were worth $12,609,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of AMGN. Brighton Jones LLC boosted its stake in Amgen by 23.5% in the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company's stock worth $7,159,000 after purchasing an additional 5,226 shares in the last quarter. Heck Capital Advisors LLC acquired a new position in shares of Amgen during the fourth quarter valued at $36,000. Virtue Capital Management LLC lifted its stake in shares of Amgen by 14.0% during the fourth quarter. Virtue Capital Management LLC now owns 775 shares of the medical research company's stock valued at $202,000 after acquiring an additional 95 shares during the period. Menard Financial Group LLC acquired a new position in shares of Amgen during the fourth quarter valued at $79,000. Finally, Park Square Financial Group LLC acquired a new position in shares of Amgen during the fourth quarter valued at $130,000. Institutional investors and hedge funds own 76.50% of the company's stock.

Analyst Upgrades and Downgrades

AMGN has been the topic of several research reports. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $305.00 price target on shares of Amgen in a research note on Tuesday, June 24th. William Blair reissued an "outperform" rating on shares of Amgen in a research note on Tuesday, June 24th. Wall Street Zen lowered Amgen from a "buy" rating to a "hold" rating in a research note on Saturday, August 9th. Raymond James Financial started coverage on Amgen in a research note on Wednesday, September 3rd. They issued a "market perform" rating on the stock. Finally, Bank of America increased their target price on Amgen from $252.00 to $261.00 and gave the company an "underperform" rating in a research note on Wednesday, July 23rd. Seven research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Amgen currently has a consensus rating of "Hold" and a consensus target price of $309.15.

Insiders Place Their Bets

In related news, SVP Nancy A. Grygiel sold 1,267 shares of the business's stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $296.99, for a total transaction of $376,286.33. Following the sale, the senior vice president owned 7,209 shares in the company, valued at $2,141,000.91. The trade was a 14.95% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.76% of the stock is owned by corporate insiders.

Amgen Stock Performance

Shares of NASDAQ AMGN opened at $279.22 on Thursday. The company has a current ratio of 1.31, a quick ratio of 0.98 and a debt-to-equity ratio of 7.24. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $335.88. The stock has a 50 day moving average of $289.84 and a 200-day moving average of $289.92. The company has a market capitalization of $150.32 billion, a P/E ratio of 22.83, a P/E/G ratio of 2.49 and a beta of 0.49.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The medical research company reported $6.02 earnings per share for the quarter, beating the consensus estimate of $5.28 by $0.74. Amgen had a return on equity of 174.71% and a net margin of 18.96%.The firm had revenue of $9.18 billion during the quarter, compared to analysts' expectations of $8.86 billion. During the same period in the previous year, the firm earned $4.97 EPS. The company's quarterly revenue was up 9.4% compared to the same quarter last year. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. As a group, equities research analysts predict that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, September 12th. Investors of record on Friday, August 22nd were given a dividend of $2.38 per share. The ex-dividend date was Friday, August 22nd. This represents a $9.52 dividend on an annualized basis and a yield of 3.4%. Amgen's payout ratio is currently 77.84%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.